Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1B | Q00975 | 14/20 | 0.41 |
| ▸ | MMP1 | P03956 | 1/20 | 0.37 |
| ▸ | MMP2 | P08253 | 1/20 | 0.37 |
| ▸ | MMP9 | P14780 | 1/20 | 0.37 |
| ▸ | MMP12 | P39900 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | GSTA2 | P09210 | 1/20 | 0.35 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.35 |
| ▸ | GSTM1 | P09488 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9595632 | 0.71 | MMP1 (0.50) | CACNA1BMMP1MMP2MMP9MMP12 | |
| SCHEMBL11883042 | 0.71 | MMP1 (0.50) | CACNA1BMMP1MMP2MMP9MMP12 | |
| SCHEMBL10362771 | 0.68 | EPHX1 (0.50) | NPC1MEN1KMT2A | |
| SCHEMBL14275000 | 0.68 | MMP1 (0.50) | CACNA1BMMP1MMP2MMP9MMP12 | |
| SCHEMBL9595626 | 0.68 | MMP1 (0.50) | CACNA1BMMP1MMP2MMP9MMP12 | |
| SCHEMBL14275010 | 0.68 | MMP1 (0.50) | CACNA1BMMP1MMP2MMP9MMP12 | |
| SCHEMBL9595631 | 0.68 | MMP1 (0.50) | CACNA1BMMP1MMP2MMP9MMP12 | |
| SCHEMBL1158019 | 0.66 | MMP1 (0.51) | CACNA1BMMP1MMP2MMP9MMP12 | |
| SCHEMBL1158016 | 0.66 | MMP1 (0.51) | CACNA1BMMP1MMP2MMP9MMP12 | |
| SCHEMBL12123424 | 0.66 | MMP1 (0.54) | CACNA1BMMP1MMP2MMP9MMP12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7429658-B2 | Synthesis of protected pyrrolobenzodiazepines | SPIROGEN LIMITED (GB) | 2008-09-30 | — | — | US | disclosed |
| US-20060264622-A1 | Synthesis of protected pyrrolobenzodiazepines | SPIROGEN LIMITED (GB) | 2006-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264622-A1 | Synthesis of protected pyrrolobenzodiazepines | SBDS, DRD2, GRIN2D | CACNA1B 364/4885MMP1 4840/4885MMP2 4399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.